Prevention of graft versus host disease with Hematopoietic Cell Transplantation with Reduced Intensity Conditioning—a comparison of three prophylaxis regimens (tacrolimus/mycophenolate mofetil/cyclophosphamide, tacrolimus/methotrexate/bortezomib or tacrolimus/methotrexate/maraviroc) versus tacrolimus/methotrexate: a randomised phase 2 trial with a non-randomised contemporaneous control group (BMT CTN 1203)

BACKGROUND. Prevention of GVHD without malignant relapse reflects the overall goal of allogeneic hematopoietic cell transplantation (HCT). Novel regimens utilizing either maraviroc (MVC), bortezomib (BOR), or post-transplant cyclophosphamide (PTCy) have been reported to modulate GVHD and were tested...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Lancet Haematol
Main Authors: Bolaños-Meade, Javier, Reshef, Ran, Fraser, Raphael, Fei, Mingwei, Abhyankar, Sunil, Al-Kadhimi, Zaid, Alousi, Amin M., Antin, Joseph H., Arai, Sally, Bickett, Kate, Chen, Yi-Bin, Damon, Lloyd E., Efebera, Yvonne A, Geller, Nancy L., Giralt, Sergio A., Hari, Parameswaran, Holtan, Shernan G., Horowitz, Mary M., Jacobsohn, David A., Jones, Richard J., Liesveld, Jane L., Logan, Brent R., MacMillan, Margaret L., Mielcarek, Marco, Noel, Pierre, Pidala, Joseph, Porter, David L, Pusic, Iskra, Sobecks, Ronald, Solomon, Scott R., Weisdorf, Daniel J., Wu, Juan, Pasquini, Marcelo C., Koreth, John
Formato: Artigo
Idioma:Inglês
Publicado em: 2019
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6503965/
https://ncbi.nlm.nih.gov/pubmed/30824040
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S2352-3026(18)30221-7
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados